Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial

Stephen J. Nicholls, Kausik K. Ray, Christie M. Ballantyne, Lauren A. Beacham, Debra L. Miller, Giacomo Ruotolo, Steven E. Nissen, Jeffrey S. Riesmeyer

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Background and aims The optimal approaches to management of patients treated with moderate statin doses on lipid parameters are unknown. The ACCENTUATE study aimed to compare the effects of adding the cholesteryl ester transfer protein inhibitor (CETP) evacetrapib, ezetimibe or increasing statin dose in atorvastatin-treated high-vascular risk patients on lipid parameters. Methods 366 patients with atherosclerotic cardiovascular disease (ASCVD) and/or diabetes were treated with atorvastatin 40 mg/day for 28 days prior to randomization to atorvastatin 40 mg plus evacetrapib 130 mg, atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg or atorvastatin 40 mg plus placebo, daily for 90 days at 64 centers in the United States. Lipid parameters, safety and tolerability were measured. Results Addition of evacetrapib significantly reduced LDL-C (−33%) compared with ezetimibe (−27%, p=0.045), increasing statin dose (−6%) and statin alone (0%, p
Original languageEnglish
Pages (from-to)12-18
Number of pages7
JournalAtherosclerosis
Volume261
DOIs
Publication statusPublished or Issued - 1 Jun 2017

Keywords

  • CETP
  • Cardiovascular disease
  • Clinical trials
  • Lipids

Cite this